Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk, a world leader in diabetes care, announced today that the European Commission (EC) has approved the expanded use of Tresiba® (insulin degludec) for children and adolescents with diabetes aged one to 17 years. The extension to the licence is available to patients in the UK with immediate effect.
The approval for expanded use of insulin degludec in children and adolescents is based on efficacy and tolerability data from the BEGIN® YOUNG 1 trial, which is being presented today at the Diabetes UK Professional Conference.
http://www.europeanpharmaceuticalre...n-and-adolescents-with-diabetes/#.VQCESfysWAg
The approval for expanded use of insulin degludec in children and adolescents is based on efficacy and tolerability data from the BEGIN® YOUNG 1 trial, which is being presented today at the Diabetes UK Professional Conference.
http://www.europeanpharmaceuticalre...n-and-adolescents-with-diabetes/#.VQCESfysWAg